Integrated analysis identifies P4HA2 as a key regulator of STAT1-mediated colorectal cancer progression and a potential biomarker for precision therapy
Our findings reveal P4HA2 promotes CRC progression and suppresses anti-tumor immunity via STAT1/PD-L1 axis regulation. This study uncovers a novel pathogenic mechanism, positioning P4HA2 as a potential therapeutic target in CRC.
Authors
- Huanle Wang
- Shasha Shi
- Guohong Dai (ORCID: https://orcid.org/0000-0002-9122-2009)
- Zhiwei Sun (ORCID: https://orcid.org/0000-0001-7899-9676)
- Qianshi Zhang (ORCID: https://orcid.org/0000-0002-3336-9934)
- Shuangyi Ren (ORCID: https://orcid.org/0000-0002-5713-6983)
- Yinan Zhang (ORCID: https://orcid.org/0000-0002-0362-1473)
- Yue Meng (ORCID: https://orcid.org/0000-0003-1058-054X)
Institutions
- Dalian Medical University (CN)
- Second Affiliated Hospital of Dalian Medical University (CN)
Publication Details
- Journal
- Frontiers in Oncology
- Published
- 2025-05-08
- DOI
- https://doi.org/10.3389/fonc.2025.1581860
- Primary Topic
- Cytokine Signaling Pathways and Interactions
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Dalian Medical University